Capital Research Global Investors 13D and 13G filings for BioMarin Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-13 2:14 pm Purchase | 2024-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 12,991,772 6.800% | 2,217,131 (+20.58%) | Filing |
| 2024-02-09 5:46 pm Purchase | 2024-02-07 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 10,774,641 5.700% | 5,123,640 (+90.67%) | Filing |
| 2023-02-13 3:32 pm Sale | 2023-02-14 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 5,651,001 3.000% | -7,021,007 (-55.41%) | Filing |
| 2022-01-10 12:04 pm Sale | 2022-01-10 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 12,672,008 6.900% | -9,521,519 (-42.90%) | Filing |
| 2021-02-16 3:58 pm Purchase | 2021-02-16 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 22,193,527 12.200% | 189,462 (+0.86%) | Filing |